This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Spanish - Rates: 0.06 - 0.10 EUR per word Spanish to English - Rates: 0.06 - 0.10 EUR per word Italian to English - Rates: 0.06 - 0.10 EUR per word Italian to Spanish - Rates: 0.06 - 0.10 EUR per word Spanish to Italian - Rates: 0.06 - 0.10 EUR per word
English to Italian - Rates: 0.06 - 0.10 EUR per word
Italian to English: PROFILO PRODOTTO - PRODUCT PROFILE General field: Medical
Source text - Italian Profilo prodotto ECMO: Prodotto X (anticorpo anti-FXIIa)
Elemento Prodotto X (anticorpo anti-FXIIa)
Indicazioni / Uso Prevenzione della trombosi durante ossigenazione extracorporea a membrana (ECMO)
Popolazione target Pazienti infanti, pediatrici e adulti sottoposti ad ECMO per la rigenerazione cardiaca o respiratoria
Meccanismo d’azione Blocco selettivo del fattore XIIa tramite anticorpo specifico che blocca il percorso intrinseco di coagulazione che viene attivato quando il sangue entra in contatto con superfici estranee e che porta alla trombosi. Il percorso estrinseco di coagulazione che viene attivato quando i vasi sanguigni vengono tagliati (ad es. durante interventi chirurgici o trauma) rimane intatto. Di conseguenza, la trombosi può essere prevenuta senza aumentare il sanguinamento. Inoltre non è necessario un agente antagonista specifico, perché la coagulazione estrinseca rimane normale e il paziente può quindi ad es. sottoporsi ad intervento chirurgico senza prima ricorrere ad un antagonista. Il blocco del fattore XIIa non è paragonabile ad altri anticoagulanti quali warfarin o gli inibitori IIA e Xa, che bloccano completamente la coagulazione
Efficacia Rispetto ad eparina non frazionata:
• Efficacia antitrombotica da equivalente a superiore rispetto ad eparina
• Prevenzione stabile della trombosi per 1-2 settimane, nessuna necessità di ricalibrazione del dosaggio
• Riduzione degli eventi emorragici mediati da eparina durante ECMO del 90%
• Diminuzione della mortalità (principalmente dovuta alla riduzione del sanguinamento durante ECMO)
• Riduzione significativa della necessità di monitorare l’anticoagulazione
• Protezione prolungata contro trombosi al termine di ECMO per 1-2 settimane
• Riduzione del 50% nella formazione di edema mediato da bradichinina
Sicurezza / Tollerabilità Prevenzione stabile della trombosi da 1 a 2 settimane, riduzione significativa degli eventi emorragici rispetto ad eparina. Non è necessario un agente antagonista perché la parte estrinseca della coagulazione non viene inibita (a differenza degli anticoagulanti attuali) e i pazienti possono sottoporsi ad intervento chirurgico senza prima ricorrere ad un antagonista.
Controindicazioni Ipersensibilità agli anticorpi anti-FXIIa; pazienti con deficit di FXIIa
Schema di dosaggio Da settimanale a una volta ogni 2 settimane
Somministrazione Infusione/iniezione endovenosa
Presentazione Formulazione liquida. Fiale/siringhe preriempite che contengono dosi per fino a 5 kg b.w., 6-25 kg b.w., 26-100 kg b.w.
HE / Qualità della vita Diminuzione della disabilità fisica e/o mentale a lungo termine (dovuta alla diminuzione degli eventi trombotici ed emorragici)
Minor necessità di trasfusioni,
Diminuzione del costo giornaliero di ECMO per paziente: Minor utilizzo di risorse/farmaci concomitanti; minor necessità di sostituzione dell’ossigenatore a causa di una minor coagulazione sul dispositivo; concentrazione antitrombina III
Conservazione / Stabilità Da 2 °C a 8°C; ≥2 anni
Inibizione di FXIIa: Proposta di valore
Proteggerà efficacemente dalla formazione di coaguli sulle superfici artificiali (utilizzate per circolazione extracorporea, VADS e altro) inibendo selettivamente il fattore FXIIa che inibisce il percorso intrinseco di coagulazione associato alla trombosi.
Il percorso estrinseco che viene attivato quando i vasi sanguigni vengono tagliati (ad es. per intervento chirurgico o trauma), necessario per fermare il sanguinamento, non viene inibito.
Pertanto, la trombosi può essere prevenuta senza indurre rischio di sanguinamento.
Di conseguenza, i pazienti possono sottoporsi ad intervento chirurgico senza prima ricorrere ad un agente antagonista dell’anticorpo anti XIIa (perché la parte della coagulazione necessaria a fermare il sanguinamento è ancora intatta).
Il meccanismo di azione non è paragonabile agli anticoagulanti comuni quali warfarin/coumadin, inibitori IIa o Xa che bloccano completamente la coagulazione portando ad un aumento del rischio di sanguinamento per questi agenti
Translation - English ECMO Product Profile: Product X (anti-FXIIa antibody)
Element Product X (anti-FXIIa antibody)
Indication / Usage Thrombosis prevention during extracorporeal membrane oxygenation (ECMO)
Target population Neonates, pediatrics, adults on ECMO for cardiac or respiratory regeneration
Mechanism Of Action Selective blockade of Factor XIIa by a specific antibody which blocks the intrinsic pathway of coagulation which is activated when blood comes into contact with foreign surfaces and leads to thrombosis. The extrinsic pathway of coagulation which is activated when blood vessels are cut (e.g. during surgery or trauma) remains intact. As consequence thrombosis can be prevented without increasing bleeding. In addition a specific reversal agent is not needed as patients still have normal extrinsic coagulation and are able to undergo e.g. surgery without the need for prior reversal. Blockade of factor XIIa is not comparable to other anticoagulant like warfarin or IIA and Xa inhibitors which completely block coagulation
Efficacy In comparison to unfractionated heparin:
• Equivalent to superior antithrombotic efficacy compared to heparin
• Stable thrombosis prevention for 1 to 2 weeks, no need for dose adjustments
• Reduction of heparin mediated bleeding events during ECMO by 90%
• Reduced mortality (Mainly due to decreased bleeding on ECMO)
• Significant reduction in anticoagulation monitoring requirements
• Prolonged protection against thrombosis after end of ECMO for 1 to 2 weeks
• 50% reduction of bradykinin-mediated edema formation
Safety / Tolerability Stable thrombosis prevention for 1 to 2 weeks, significantly reduced bleeding events compared to heparin. No need for a reversal agent as the extrinsic part of coagulation is not inhibited (unlike current anticoagulants) and patients can undergo surgery without the need for reversal.
Contraindications Hypersensitivity against anti FXIIa antibody; patients deficient in FXIIa
Dosing / Schedule Weekly to once every 2 weeks
Administration Intravenous injection/infusion
Presentation Liquid formulation. Vials/prefilled syringes containing dose for up to 5kg b.w., 6-25kg b.w., 26-100kg b.w.
HE / Quality Of Life Reduced long term mental and/or physical disability (Due to decreased thrombotic events, decreased bleeding)
Decreased transfusion requirements,
Decreased cost per day on ECMO per patient: Decreased resource/ concomitant medication utilization, reduction in need for oxygenator exchange due to reduced device clotting, Antithrombin III concentrates
Storage / Stability 2 to 8°C; ≥2yrs
Inhibition of FXIIa: Value proposition
Will effectively protect against clot formation on artificial surfaces (as used in extracorporeal circulation, VADS and elsewhere) by selectively inhibiting factor FXIIa which inhibits the intrinsic pathway of coagulation associated with thrombosis.
The extrinsic pathway which is activated when blood vessels are cut (e.g. surgery or trauma) and needed to stop bleeding is not inhibited.
Therefore thrombosis can be prevented without inducing a bleeding risk
As consequence patients can undergo surgery without the need of previous reversal of the anti XIIa antibody (because the part of the coagulation cascade needed to stop bleeding is still intact).
This mechanism of action is not comparable to common anticoagulants like warfarin/coumadin, IIa or Xa inhibitors which completely block coagulation which leads to an increases bleeding risk for these agents
Spanish to English: LAS COSAS NO SON SIEMPRE LO QUE PARECEN - THINGS AREN’T ALWAYS WHAT THEY SEEM General field: Marketing Detailed field: Business/Commerce (general)
Source text - Spanish La Verdad convincente crea parámetros claros para la toma de decisión a todo nivel en tu negocio. Actúa como fundamento para un alineamiento al que toda comunicación debe basarse para que sea sostenible y tenga credibilidad.
Old Mutual era un nombre conocidísimo dentro del mercado. Pero a nivel internacional era menos conocido y en algunos países el propio nombre tenía connotación negativa. Esto contradecía la verdad sobre la marca. Así que, con el objeto de poder acceder a nuevos mercados, se desarrolló una estrategia para aprovechar sus puntos fuertes así como el patrimonio local, de tal manera que fuese convincente en el escenario internacional y conforme a la marca.
La oferta, la estructura, el posicionamiento y la personalidad de tu marca son hasta cierto punto un reflejo de lo que está pasando dentro de tu organización. Sin embargo, si la promesa de tu marca no se ajusta al modo en el que tu negocio se comporta o a lo que aporta, la verdad saldrá a la luz, dañando la credibilidad de tu marca. Se deben realizar esfuerzos constantes para garantizar que todos esos elementos sigan siendo coherentes, verdaderos y significativos para el mundo exterior.
Translation - English Compelling Truth creates clear benchmarks for decision making at every level of your business. It acts as the bedrock for alignment around which all communication must be based for it to be sustainable and credible.
Old Mutual was a household name in its own market. But internationally it was less well known, and in some countries the name itself had negative connotations. This belied the truth of the brand. So, in order for it to enter new markets, a strategy was developed to build on its strengths and local heritage in a way that was true to its brand yet compelling on the international stage.
Your brand’s offer, structure, positioning and personality cannot help but reflect what’s going on inside your organization to some degree. However, if your brand promise slips out of kilter with the way your organization behaves or what it delivers, the truth will out, damaging the credibility of your brand. Continuing efforts must be made to ensure that these elements remain consistent, true to your business and meaningful to the outside world.
English to Spanish: GENERAL TERMS AND CONDITIONS OF AUCTION - CONDICIONES GENERALES DE LA LICITACIÓN General field: Law/Patents Detailed field: Law: Contract(s)
Source text - English GENERAL TERMS AND CONDITIONS OF AUCTION
2.1 [...] will evaluate the auction bids received and issue an award decision in favour of the highest acceptable bid among those submitted by the bidding parties for each of the lots of the Auction, provided that they equal or exceed their respective sales values. The awarding of the lot will be declared null and void if no bid is received in accordance with the terms and conditions of the bidding procedure, or if those received do not equal or exceed the sales values, as set out in the Annex No.1 of the Rules and Regulations or in the legal positions to be established.
2.2 The sale of the Assets, the object of the present Auction, will take place according to the physical state of the individual assets and in the place of their current location.
Translation - Spanish CONDICIONES GENERALES DE LA LICITACIÓN
2.1 [...] evaluará las ofertas recibidas y emitirá el fallo de adjudicación a favor de la oferta más alta y aceptable de las presentadas por los licitantes para cada uno de los lotes de la Licitación, siempre y cuando iguale o supere el valor para venta. La adjudicación del lote se declarará desierta cuando no se haya recibido ninguna oferta en términos de las presentes Bases, o cuando las recibidas no igualen o superen el valor para venta, y que se señala en el Anexo No.1 de las presentes Bases o a las posturas legales que se establezcan .
2.2 La venta de los Bienes objeto de la presente Licitación se efectuará en el estado fisico en que se encuentran y en el lugar de su ubicación actual.
More
Less
Translation education
Master's degree - The Università degli Studi di Napoli "L'Orientale"
Experience
Years of experience: 10. Registered at ProZ.com: Aug 2017.
I am a professional freelance translator, enrolled with the Court of Santa Maria Capua Vetere (Italy) C.T.U. Register of Foreign Languages experts (translator and interpreter) for the following language pairs:
Italian < > Spanish Italian < > English English < > Spanish
After studying literary translation in Italy – my home country – at the University of Naples "L'Orientale" I obtained a Master of Publishing and Communications from Comunika Institute in Rome and I specialized in legal, medical-pharmaceutical and marketing translation, gaining wide experience abroad. I currently collaborate with translation agencies, consulting and service companies, as well as with private clients in Spain, Ireland and Italy.
Keywords: translation, traducción, Italian, Spanish, English, Italiano, Español, Inglés, literary translation, traducción literaria. See more.translation, traducción, Italian, Spanish, English, Italiano, Español, Inglés, literary translation, traducción literaria, legal translation, traducción legal, sworn translation, traducción jurada, medical-pharmaceutical translation, traducción médico-farmacéutica, marketing and advertising, publicidad y marketing, editing and proofreading, edición y corrección, audio and video transcription, transcripción de vídeo y audio, project management, gestión de proyectos. See less.
Expertise